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Abstract
Define and identify long-term non-progressors (LTNP) and HIV controllers (HIC), and estimate time until disease progression.
LTNP are HIV-1
+ patients who maintain stable CD4
+ T-cell counts, with no history of opportunistic infection or antiretroviral
therapy (ART). HIC are a subset of LTNP who additionally have undetectable viraemia. These individuals may provide
insights for prophylactic and therapeutic development. Records of HIV-1
+ individuals attending Chelsea and Westminster
Hospital (1988–2010), were analysed. LTNP were defined as: HIV-1
+ for .7 years; ART-naı ¨ve; no history of opportunistic
infection and normal, stable CD4
+ T-cell counts. MIXED procedure in SAS using random intercept model identified long-
term stable CD4
+ T-cell counts. Survival analysis estimated time since diagnosis until disease progression. Subjects
exhibiting long-term stable CD4
+ T-cell counts with history below the normal range (,450 cells/ml blood) were compared to
LTNP whose CD4
+ T-cell count always remained normal. Within these two groups subjects with HIV-1 RNA load below limit
of detection (BLD) were identified. Of 14,227 patients, 1,204 were diagnosed HIV-1
+ over 7 years ago and were ART-naı ¨ve.
Estimated time until disease progression for the 20% (239) whose CD4
+ T-cell counts remained within the normal range, was
6.2 years (IQR: 2.0 to 9.6); significantly longer than 4.0 years (IQR: 1.0 to 7.3) for patients with historical CD4
+ T-cell count
below normal (Logrank chi-squared=21.26; p,0.001). Within a subpopulation of 312 asymptomatic patients, 50 exhibited
long-term stable CD4
+ T-cell counts. Of these, 13 were LTNP, one of whom met HIC criteria. Of the remaining 37 patients
with long-term stable low CD4
+ T-cell counts, 3 controlled HIV-1 RNA load BLD. Individuals with stable, normal CD4
+ T-cell
counts progressed less rapidly than those with low CD4
+ T-cell counts. Few LTNP and HIC identified in this and other
studies, endorse the need for universal definitions to facilitate comparison.
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Introduction
The majority of HIV-1 infected patients display a gradual
decline in peripheral blood CD4
+ T cells throughout the course of
their illness. This is accompanied by excessive immune activation
and the sequential loss of immune responses, first to HIV-1, then
to other pathogens, allogeneic stimuli and finally mitogens [1,2].
The rate of disease progression from asymptomatic HIV-1
infection to AIDS varies between patients [3], and determination
of factors associated with progression may enable the development
of therapeutic or prophylactic vaccines to abrogate disease or
prevent infection.
AIDS defining illnesses were originally used as clinical indicators
of HIV-1 disease progression, however in 1993 the USA widened
their definition of AIDS to include a decline in peripheral blood
CD4
+ T-cell count to less than 200 cells/ml blood or less than 14%
of lymphocytes [4]. Some HIV-1
+ patients are able to maintain
stable CD4
+ T-cell counts within the normal healthy range
(between 450–1650 cells/ml blood; local laboratory reference
range [5]) for a prolonged length of time and remain asymptom-
atic without antiretroviral therapy (ART). These patients have
been referred to as long-term non-progressors (LTNP). Within this
group of atypical patients a few, known as HIV controllers (HIC),
suppress HIV-1 replication below the limit of detection of the
HIV-1 RNA plasma load assay (BLD; ,50 HIV-1 RNA copies/
ml plasma) [5,6]. Studying such atypical patients has the potential
to provide insight into the control of HIV-1 infection in the
absence of therapeutic intervention [7]. Despite the identification
and study of LTNP and HIC in many international single- and
multi-centre HIV cohorts, consistent definitions have not been
uniformly applied across all studies and sites. Confusion about
definitions used also exists in the published literature, resulting in
difficulties when comparing results from patient groups within
different cohorts.
The Chelsea and Westminster HIV cohort is the largest single-
centre HIV cohort in Europe and is very well documented, with
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facilitating longitudinal analyses. LTNP within the Chelsea and
Westminster HIV cohort are defined by a duration of HIV-1
infection longer than 7 years from time of HIV-1
+ diagnosis, in the
absence of ART and clinical symptoms, and the stable
maintenance of CD4
+ T-cell count within the normal reference
range used by the laboratory and HIV clinicians during routine
clinical follow-up (450–1650 cells/ml blood) [3,5,7]. Within this
group of patients, a minority, termed HIV controllers (HIC) also
control HIV-1 replication to BLD of the conventional HIV-1
RNA load assay; in the past the threshold of viral load detection
was 500 HIV-1 RNA copies/ml plasma, but the current assays
now have a detection limit of 50 HIV-1 RNA copies/ml plasma
[5]. Another group of patients had a history of long-term stable
CD4
+ T-cell counts that on at least one occasion were below the
normal range, and these individuals were identified as having long-
term stable low CD4
+ T-cell counts. Amongst this group, patients
who exhibited control of HIV-1 RNA load replication to BLD
were also identified (Figure 1).
The aims of this study were firstly, to estimate the time until
HIV-1 disease progression in groups of patients identified as
LTNP during the study period by the application of different
selection criteria; secondly to identify the frequency of HIV-1
+
patients belonging to the Chelsea and Westminster HIV cohort
who, at the end of the study period, fulfilled the criteria of LTNP
and HIC; and thirdly, to report immunological and virological
profiles in the patient groups identified.
Methods
Ethics Statement
Data analyses were conducted on anonymised data and this
study was approved by the Riverside Research Ethics Committee
(now known as London Riverside National Research Ethics
Service [NRES] Committee.
Study sample
Data for each patient in the entire Chelsea and Westminster
HIV cohort from 1
st January 1988 until 28
th February 2010 were
extracted from our local database and screened to identify LTNP,
HIC, patients with long-term stable low CD4
+ T-cell counts, and
amongst these a subset of patients who also controlled HIV-1
RNA load BLD.
Cohort selection criteria
The Chelsea and Westminster HIV Cohort LTNP selection
criteria were applied to identify patients with documented HIV-1
infection for greater than seven years. The duration of HIV-1
infection was derived from the date of first positive HIV-1 test
result or, if this was unavailable prior to enrolment into the local
HIV cohort, the earliest clinic visit date was used. The second
criterion for patient selection was never receiving ART. Thirdly
these patients were screened for history of opportunistic infection
(OI). OI was defined as any symptomatic manifestation of HIV-1
illness described in the medical record. Entries of ‘‘acute
infection’’, ‘‘persistent generalized lymphadenopathy (PGL)’’,
and ‘‘asymptomatic infection’’ were not defined as OI. The fourth
selection criterion used was patients who had a stable CD4
+ T-cell
count. This was defined as a CD4
+ T-cell count slope of $0 cells/
ml blood from entry into cohort until the most recent available
CD4
+ T-cell count. Analyses were performed by grouped 3
monthly time periods because, on average, clinically stable HIV-1
+
patients are seen at quarterly intervals in our cohort.
Statistical methods
As longitudinal data on CD4
+ T-cell count were available,
with multiple assessments of CD4
+ T-cell count on the same
patient at different time points, within patient assessments at
different time points were expected to be correlated. This
correlation needed to be accounted for when selecting analytical
methods [8].
The statistical analyses using longitudinal data needed to
consider four main characteristics: i) time may be an explanatory
variable; ii) repeat CD4
+ T-cell count measurements for a patient
are likely to be correlated; iii) the co-variables may be time-
dependent, showing variation through time for a patient; and
iv) missing data in the successive CD4
+ T-cell count measure-
ments may induce a bias. A repeated measures linear mixed model
was used to derive time adjusted CD4
+ T-cell count slope, or
rate of change per quarter in CD4
+ T-cell count since entry to
cohort [9].
The MIXED procedure in Statistical Analysis Software
(Version 9.1.3; SAS Institute Inc., Cary, NC, USA) was used by
fitting values of CD4
+ T-cell counts from all available results at
different time points as a dependent variable grouped into 3
monthly intervals. A random intercept model was fitted using
MIXED procedure in SAS. The independent variables included
the fixed effects of subjects and clinic visit time points grouped into
3-month intervals. This assumed that the intercept for each patient
was random and the effects of CD4
+ T-cell count changes (slopes)
from baseline (at entry into the cohort) were also random and
differed between subjects. A compound symmetry covariance
matrix was used to model the within patient errors. This assumed
that the variances were homogeneous. Correlation existed
between two separate measurements, but it was assumed that
the correlation was constant regardless of the time between
successive CD4
+ T-cell count measurements [10]. Estimates of
CD4
+ T-cell count slopes were obtained from patient by time
interaction. All patients whose CD4
+ T-cell counts were stable
since cohort entry were assumed to show either no change or have
an increase in CD4
+ T-cell count since entry to cohort, indicated
by a slope $0 cells/ml blood (i.e. no decline in CD4
+ T-cell count).
Those patients whose CD4
+ T-cell count slope was negative were
assumed to have an unstable, declining CD4
+ T-cell count over
time, and were therefore excluded from selection. After excluding
patients who had died, a further refined selection criterion was
applied to patients who had stable CD4
+ T-cell counts. Patients
were defined as LTNP, who had a stable CD4
+ T-cell count which
continuously remained within the normal range throughout
clinical follow-up. These were compared with those patients
whose CD4
+ T-cell counts were stable but had at least one
recorded CD4
+ T-cell count below the normal range (,=450
cells/ml blood) and referred to as patients with long-term stable low
CD4
+ T-cell counts.
The Mann-Whitney U test was used for between group
comparisons of non parametric data while qualitative data are
presented as numbers with percentages and compared using the
chi-squared test statistic and where appropriate corrected with
Yates’ correction.
Survival analysis was used to estimate time from HIV-1
+
diagnosis until disease progression in a group of patients who
had been diagnosed HIV-1
+ for longer than 7 years, and who
had not been prescribed ART (n=1,204). Progression in this
group was defined as presentation with symptomatic or
AIDS-defining illness or declining CD4
+ T-cell count during
follow-up.
Time from HIV-1
+ diagnosis until HIV-1 disease progression
was estimated in 312 patients, a subset of the initial 1,204, who
Long-Term Non-Progressors and HIV Controllers
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+ for longer than 7 years, had not been
prescribed ART and who remained asymptomatic. Progression in
this group was assessed through evidence of unstable CD4
+ T-cell
counts during follow up, or death.
Joint probabilities of non-progression for more than 7 years, and
remaining ART-naı ¨ve, in patients who fulfilled criteria of LTNP
but eventually exhibited HIV-1 disease progression, was used to
estimate progression time. This was estimated since the date of
HIV-1
+ diagnosis until each of the defined criteria indicative of
HIV-1 disease progression. Data were censored at the most recent
visit to the clinic. The progression times are estimated and
presented stratified by groups of patients whose CD4
+ T-cell count
either remained within, or was outside on at least one occasion, the
normal range.
Figure 1. Flow chart detailing the identification of LTNP and patients with long-term stable low CD4
+ T-cell counts from the Chelsea
and Westminster HIV Cohort, during the study period 1988–2010.
doi:10.1371/journal.pone.0029844.g001
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Demographic characteristics
From a total of 14,227 HIV-1
+ patients in the study cohort,
5,417 subjects were identified as being diagnosed HIV-1
+ for more
than 7 years (Figure 1). Of these, 1,204 had never been prescribed
ART of whom 19.9% had CD4
+ T-cell count history that
consistently remained within the normal range. There were no
significant differences between patients whose CD4
+ T-cell count
remained within the normal range compared to patients whose
CD4
+ T-cell count had been documented below the normal range;
in terms of gender (90.8% and 92.3% male respectively; p=0.515)
or median age (39.9 and 40.2 years respectively; p=0.485).
Significantly fewer Caucasians were seen in the group whose
CD4
+ T-cell count remained within normal range compared to
patients whose CD4
+ T-cell count had been recorded on at least
one occasion as below the normal range (58.2% and 68.5%
respectively; p=0.003).
Of 1,204 ART-naı ¨ve individuals who had been HIV-1
+ for
longer than 7 years, 312 (25.9%) remained asymptomatic, with
258 patients (83%) exhibiting unstable CD4
+ T-cell counts
(Table 1, Figure 1). A significant difference in median highest
recorded HIV-1 load in patients who had an unstable CD4
+ T-cell
count was observed when compared to those who exhibited stable
CD4
+ T-cell counts; 39,022 (IQR: 10,935 to 120,580) compared
to 12,769 (IQR: 1,547 to 64,902) HIV-1 RNA copies/ml plasma
respectively (p=0.007). No significant differences were seen in
immunological parameters investigated between patients with
stable and unstable CD4
+ T-cell counts (Table 1).
Time until HIV-1 disease progression
Of the 1,204 patients, 239 patients whose CD4
+ T-cell counts
remained within the normal range had an estimated time until
HIV-1 disease progression since HIV-1
+ diagnosis of 6.2 (IQR: 2.0
to 9.6) years, compared to 4.0 (IQR: 1.0 to 7.3) years for the 965
patients who had at least one CD4
+ T-cell count below the normal
range (Logrank chi-squared=21.26, p,0.001; Table 2).
Of the 312 (26%) ART-naı ¨ve patients who had been diagnosed
HIV-1
+ for longer than 7 years and remained asymptomatic
during the course of their routine HIV-1 follow up, 110 (35.3% of
312) maintained CD4
+ T-cell counts within the normal range.
These patients had an estimated median time until CD4
+ T-cell
count decline (or clinical progression) of 9.1 (IQR: 4.0 to 20.2)
years while for the remaining 202 patients who had at least one
CD4
+ T-cell count fall below the normal range this was 7.3 (IQR:
2.3 to 13.3) years (Logrank chi-squared=3.72, p=0.054; Table 2).
Frequency of unstable CD4
+ T-cell count
Of the 312 ART-naı ¨ve patients diagnosed as HIV-1
+ for longer
than 7 years who remained asymptomatic during the course of
their routine HIV-1 follow up, 258 (82.7%) had unstable or
declining CD4
+ T-cell counts. Of these 95 (36.8%) had CD4
+ T-
cell counts consistently within the normal range and the estimated
median time until HIV-1 disease progression in this group was 5.8
(IQR: 2.3 to 8.6) years, this was similar to the 163 patients (63.2%
of 258) who had a history of CD4
+ T-cell counts below the normal
range with an estimated time until HIV-1 disease progression of
4.6 (IQR: 1.8 to 8.4) years (Logrank chi-squared=0.045,
p=0.833; Table 2).
Frequency of long-term stable low CD4
+ T-cell count and
LTNP
A total of 50 ART-naı ¨ve patients were identified as having long-
term stable CD4
+ T-cell counts. HIV-1 RNA plasma load data
from these 50 living patients were investigated, and for four
patients this was found to be consistently BLD of the viral load
assay used. Of these 50 patients, 13 patients consistently had CD4
+
T-cell counts within the normal range. These were classified as
LTNP (Figure 1), while 1 patient (7.7%) was identified as an HIC.
The remaining 37 patients who exhibited long-term stable low
CD4
+ T-cell counts, all had at least one recorded CD4
+ T-cell
count below the normal range. Three of these 37 controlled HIV-
1 replication to BLD. CD4
+ T-cell count profiles over time since
HIV-1
+ diagnosis of the 13 LTNP are depicted in Figure 2A and
for those with long-term stable low CD4
+ T-cell count in
Figure 2B. All of these 50 individuals displayed a stable slope of
$0 cells/ml blood, per quarter.
Demographic characteristics – comparison of groups of
patients with long-term stable low CD4
+ T-cell count and
LTNP
No significant differences were found in gender, ethnicity, age
or HIV-1 risk between patients classified as exhibiting long-term
stable low CD4
+ T-cell count and LTNP (Table 1). Duration since
HIV-1
+ diagnosis, nadir CD4
+ and recent CD8
+ T-cell counts
were significantly higher in LTNP compared to the patients with
long-term stable low CD4
+ T-cell count.
Discussion
Of the 6,390 HIV-1
+ patients currently attending our centre for
HIV treatment and care, 13 (0.20%) have been identified in this
study as LTNP, of whom one (0.02%) was an HIC. Thirty-seven
(0.58%) were classified as exhibiting long-term stable low CD4
+ T-
cell counts, of whom 3 (0.05%) were able to control their HIV-1
RNA load replication BLD. This demonstrates that the number of
patients fulfilling the criteria used to define LTNP, HIC or long-
term stable low CD4
+ T-cell counts within the Chelsea and
Westminster HIV cohort is very small.
Studies on HIV-1
+ non-progressors to date have used varying
definitions based on duration of HIV-1 infection and CD4
+ T-cell
counts to identify atypical patient groups (Figure 3). In addition,
most studies select these atypical patients who maintain their
CD4
+ T-cell count profile within the normal range. This study
suggests that by using varying selection criteria, disease progression
is very likely in the majority of people living with HIV-1. The
patients who had not progressed within the study period are likely
to do so, as demonstrated in the analysis of individuals found to
have long-term stable low CD4
+ T-cell counts compared to those
with unstable CD4
+ T-cell counts.
The Chelsea and Westminster HIV Cohort selection criteria
included the stringent criterion of a non-declining CD4
+ T-cell
count slope since cohort entry, combined with additional clinical
criteria as reported here. Despite having used one of the largest
HIV-1
+ cohorts in Europe to identify these atypical patients, only
50 (0.38%) exhibited maintenance of a long-term stable CD4
+ T-
cell count, of whom only 13 could be confirmed as LTNP. Data on
our cohort are routinely collected, and like other observational
databases patients can be lost to follow up. Another limitation of
observational data from a single centre is that HIV-1
+ patients can
also be managed in other centres and may receive ARV treatment
from other clinical care providers, including private practice,
which may not be captured in the database of the single centre.
The formation of a national centralised observational database
would be one strategy to overcome such limitations whilst
clinicians are currently reliant on patients’ self reporting of
treatment, including ART received elsewhere.
Long-Term Non-Progressors and HIV Controllers
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+ T-cell counts.
n=312 n=54
Unstable CD4
+ T-cell
count
Stable CD4
+ T-cell
count ‘p-value
Long-term stable low
CD4
+ T-cell count LTNP ‘p-value
(Total=258) (Total=54) (Total=39) (Total=15)
Alive at most n=243
{ n=50
{ n=37
{ n=13
{
recent time point (Died n=15) (Died n=4) (Died n=2) (Died n=2)
Demographics
Gender (%)
Female 26(10.7) 4(8.0) 3 (8.1) 1 (7.7)
Male 217(89.3) 46(92.0) 0.751 34 (91.9) 12 (92.3) 0.584
Ethnicity (%)
Caucasian 157 (64.6) 34 (68.0) 22 (59.5) 12 (92.3)
Black African 16 (6.6) 2 (4.0) 2 (5.4) 0 (0.0)
Other 70 (28.8) 14 (28.0) 0.766 13 (35.1) 1 (7.7) 0.090
Median age at last 39.9 42.7 41.7 40.2
visit, years (35.2 to 46.3) (36.8 to 49.9) (36.4 to 50.6) (39.2 to 45.4)
(IQR) [range] [23.5 to 69.5] [24.9 to 68.0] 0.078 [24.9 to 67.1] [29.6 to 68.0] 0.782
HIV risk (%)
MSM 213 (87.7) 44 (88.0) 34 (91.9) 10 (76.9)
Heterosexual 28 (11.5) 3 (6.0) 2 (5.4) 1 (7.7)
Bisexual 2 (0.8) 3 (6.0) 0.021 1 (2.7) 2 (15.4) 0.234
Median time since 10.1 10.2 9.3 11.9
HIV-1
+ diagnosis, (8.3 to 13.7) (8.1 to 14.2) (7.6 to 13.0) (9.4 to 19.4)
years (IQR) [range] [7.0 to 23.2] [7.0 to 24.1] 0.995 [7.0 to 23.7] [7.4 to 22.3] 0.048
Immunology
Median nadir CD4
+ 303 337 0.404 296 583
T-cell count, cells/ml (226 to 415) (229 to 460) (194 to 350) (512 to 675)
blood (IQR) [range] [18 to 1055] [17 to 1043] [17 to 400] [460 to 1043] ,0.001
Median most recent 978 1067 946 1222
CD8
+ T-cell count, (714 to 1302) (755 to 1293) (712 to 1219) (1185 to 1624)
cells/ml blood [168 to 3255] [328 to 3168] 0.613 [328 to 1803] [721 to 3168] 0.015
(IQR) [range]
Median nadir CD19
+ 90 100 112 94
B-cell count, cells/ml (61 to 140) (59 to 176) (53 to 187) (70 to 157)
blood (IQR) [range] [4 to 584] [15 to 348] [15 to 348] [41 to 269]
n=147 n=46 0.354 n=34 n=12 0.881
Median nadir 38 52 52 52
CD16/56 natural killer (18 to 80) (24 to 89) (25 to 90) (24 to 61)
cell count, cells/ml [2 to 362] [3 to 226] [11 to 226] [3 to 191]
blood (IQR) [range] n=129 n=42 0.218 n=32 n=10 0.701
Virology
Median highest 39022 12769 13022 3113
recorded HIV-1 load, (10935 to 120580) (1547 to 64902) (3424 to 66433) (1100 to 42238)
RNA copies/ml [,50 to 544551] [,50 to 533774] [,50 to 533774] [,50 to 481775]
plasma (IQR) [range] n=130 n=44 0.007 n=32 n=12 0.377
Where data is unavailable for all patients within a group, the number of patients for whom data available is detailed.
{, {See Figure 1 for definition of patient groups.
‘p-value using Mann-Whitney U test for quantitative data and chi-squared test with Yates’ correction for qualitative data.
doi:10.1371/journal.pone.0029844.t001
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+ diagnosis until disease progression in patients who have been infected with HIV-1 for more than 7
years and who remain symptomless in the absence of ART.
HIV-1
+ .7 years, no ART
{ HIV-1
+ .7 years, no ART
{ or OI
{
HIV-1
+ .7 years, no ART or OI, unstable
CD4
+ T-cell count
{
n=1,204
Time until disease
progression
# p-value n=312
Time until disease
progression
# p-value n=258/312
Time until disease
progression
# p-value
CD4
+ T-cell
count ever
below the
normal range?
No 239 6.2 (2.0 to 9.6) 110 9.1 (4.0 to 20.2) 95 5.8 (2.3 to 8.6)
Yes 965 4.0 (1.0 to 7.3) ,0.001 202 7.3 (2.3 to 13.3) 0.054 163 4.6 (1.8 to 8.4) 0.833
Patients are stratified according to a history of at least one CD4
+ T-cell count below the normal range (,450 cells/ml blood).
{, {See Figure 1 for definition of patient groups.
#median (IQR) years.
p-values using the Logrank chi-squared test.
doi:10.1371/journal.pone.0029844.t002
Figure 2. CD4
+ T-cell counts over the time since HIV-1
+ diagnosis of (A) 13 LTNP, one of whom fulfilled HIC status, with VLBLD, as
detailed in the key and (B) 37 patients with long-term stable low CD4
+ T-cell count, 3 of whom maintained HIV-1 RNA load to BLD.
Dashed horizontal lines indicate the normal healthy range of CD4
+ T-cell count (450–1650 cells/ml blood), and a solid vertical line shows the time
point 7 years post HIV-1
+ diagnosis. Repeated CD4 T-cell counts are plotted at the time points indicated, where different symbols represent different
individual patients.
doi:10.1371/journal.pone.0029844.g002
Long-Term Non-Progressors and HIV Controllers
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ical and virological markers of HIV-1 disease progression between
groups of patients. Current CD4
+ T-cell count, nadir CD4
+ T-cell
count and plasma HIV-1 RNA load were shown to be statistically
different between groups of patients, however no differences were
observed in CD8
+ T-cell, CD19 B-cell or CD16/56 NK cell
counts, indicating that the characteristics of HIV-1 disease, in the
groups of i) LTNP, ii) patients with long-term stable low CD4
+ T-
cell count and iii) individuals with unstable CD4
+ T-cell counts,
may be independent of the humoral and NK cell-mediated innate
immune responses. However, due to the small numbers of
individuals in the LTNP and long-term stable low CD4
+ T-cell
count groups, power to detect a statistical significance was low.
Small sample sizes decrease accuracy in point estimates used to
describe quantitative data, including immunological and virolog-
ical markers, demonstrated by increased variability. A larger
sample size would be required to reduce this variability, providing
increased statistical power, sensitive hypothesis tests and decreased
variability with narrower confidence intervals. In addition, studies
that have investigated factors influencing CD4
+ T-cell counts have
indicated that sex [11], ethnicity [12], age [13] and behavioral (i.e.
smoking) [11] factors exert significant effects on CD4
+ T-cell
counts. Such potential effects on the observations reported above
could not be performed due to small sample size, and relatively
low numbers of women and ethnic diversity in our cohort.
Furthermore, the infecting clade of HIV-1 and the geographic
origin of infection are likely to impact the course of HIV-1 disease
progression. Clade data was only available for 19/50 patients with
stable CD4
+ T-cell count, 16 of whom were infected with clade B
and 3 with clade C virus. Of the 13 patients identified as LTNP,
clade information was available for 5. Of these, 3 were infected
with clade B and 2 with clade C virus, while the infecting viral
clade for the remaining 8 LTNP has not yet been tested. Although,
the majority of HIV-1
+ individuals in the UK are infected with
clade B virus [14] the infecting clade and viral fitness are
important considerations for future work with the cases identified
herein.
It is possible that many more PLHIV are LTNP or HIC, but
due to the absence of clinical manifestations of disease these
individuals have not yet attended an HIV-1 testing facility and
consequently have not been diagnosed as HIV-1
+. The criteria of
time from HIV-1 seropositive diagnosis should also be considered
as relatively arbitrary, as the date of first HIV-1
+ test result, or date
of first attendance at an HIV clinic, may not be an accurate
representation of the date of infection. Instead, the date of first
positive HIV-1 test should be considered a tool for healthcare
professionals to identify patients exhibiting an unusual course of
HIV-1 disease.
Previously published data from our group and others further
indicate that disease progression in LTNP is ultimately inevitable,
and virological, immunological and genetic factors have all been
consistently reported to be associated with rate of disease
progression [5,15,16]. HIV-1 control is thought to be attributable
to immunological, virological and genetic components. The viral
control exhibited by LTNP and HIC has been shown to be
associated with robust, broad HIV-1-specific CD4
+ and CD8
+ T-
cell responses [5–7]. Many LTNP are HLA-B57
+, an MHC-class I
allele that demonstrates enhanced peptide presentation to
cytotoxic CD8
+ T-cells on the surface of infected CD4
+ cells
[17,18].
In our opinion, the rate of disease progression in HIV-1
+
patients should be considered a continuous variable and not
discrete. Studying patients at the extreme of this distribution may
enable discovery of correlates of HIV-1
+ disease progression,
leading to identification of targets to be manipulated by novel
therapeutic approaches, with the ultimate goal of inducing delayed
disease progression, retarding ART initiation and alleviating pill
burden and toxicity.
Reports from other cohorts where atypical groups of patients
have been identified, even though they used different criteria from
those stated here, confirm the paucity of PLHIV who could be
classified as LTNP. A recent investigation of a large HIV-1 cohort
in France identify only 0.4% of their sample as LTNP [19]. The
data presented in this and other studies emphasise a need for
collaboration with other cohorts when studying such atypical
patients, such as work performed within the international
GISHEAL consortium, to increase the number of LTNP and
HIC who can be identified and studied. In this study we
demonstrate that using different criteria to define patient groups
result in different estimates in time until disease progression, before
Figure 3. Synonyms used to describe HIV-1
+ patients exhibiting atypical disease progression. No internationally recognised consensus
for terminology currently exists, making comparison between studies difficult.
1[21,22],
2[5,6,19,23],
3[24],
4[6,18,19,24],
5[6,25],
6[19],
7[5,6,16,18,19,23,26–28],
8[16,27].
doi:10.1371/journal.pone.0029844.g003
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factors, further emphasising the need for agreed standardised use
of terminology and definitions before more in depth study of these
individuals is performed. Figure 3 provides an indication of some
of the different criteria used by different groups. Large cohorts of
well-defined HIV-1
+ patients will be essential for future investi-
gation of genetic associations with HIV-1 control and delayed
disease progression [6], as the unique immunological and
virological responses demonstrated by LTNP and HIC may
provide clues towards both the change in disease status of these
patients over time, and provide insights for HIV-1 preventive or
therapeutic vaccine development, sentiments recently reiterated by
Francoise Barre-Sinoussi as part of the preparations for the June
2011 United Nations High Level Meeting in New York [20].
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